#Orthopaedic in Sector 40

[treatmentforus]

[cardiatic-care-blog]

Premier PCD Pharma Franchise Companies in the Cardiac and Diabetic Segment

The cardiac and diabetic sectors significantly contribute to the growth of India's pharma industry, with India ranking third globally in manufacturing and exporting these medicines. The global market for diabetes drugs was valued at USD 66 billion in 2023 and is projected to reach USD 118 billion by 2032, growing at a CAGR of 6.67%. This rising demand has seen most leading cardiac diabetic PCD Pharma firms in India expand their business in the cardiac diabetic PCD franchise business model. 

That is why if you are looking for some of the leading Cardiac Diabetic PCD companies you are exactly where you need to be. However, we present below some of the best companies based on factors such as certifications, the variety of products offered, quality, packaging, prices, and profit margins in the Cardiac Diabetic Franchise Market. 

List of Top 5 PCD Pharma Franchise Companies For Cardiac Diabetic Range

If you are a pharma professional seeking information about the leading Cardiac Diabetic PCD Companies in India offering high-quality, affordable products with unchallenged production facilities, we have outlined a brief list of such companies. This list will help you in selecting the most appropriate partner for the Cardiac Diabetic PCD Pharma Franchise.

Cardiatic Care 

Cardiatic Care is a renowned Cardiac Diabetic Company in India that has offered its health products, especially the cardiac and diabetic segments since 2016. It is one of the leading PCD franchises functional under Neurocon Inc. and stocks more than 100 Patented products that have been approved by DCGI. Presently the company is accredited with ISO and there is rigor to provide excellent customer relations and increase product turnover.

Prioritizes satisfaction with transparent deals.

FSSAI and DCGI-certified products.

An ISO and WHO-approved cardiac and diabetic company.

Provides more than 100 diabetic and cardiac products at low prices.

Medications are prepared under medical direction.

Contact Details: 

Phone Number: +91 9501801421,  +91 8146662777

Email: cardiaticcare@gmail.com 

Address: SCO- 47/1, First Floor, Samadhi Gate, Old Ropar Road, Manimajra, 160101, Chandigarh

Servocare Lifesciences

Servocare Lifesciences is one of the leading cardiac diabetic PCD Franchise Companies that was founded in the year 2005 in India and deals in high-quality medicines. It aims to build a disease-free society and to provide support to pharma personnel through franchises in the cardiac and diabetes segment. A highly experienced team of professionals with over 40 years of experience Servocare is an ISO company, which offers various products approved by DCGI and FSSAI. The company has other production facilities in different countries an indication of its substantial international market outreach. 

Life Vision Healthcare

Life Vision Healthcare, a leading cardiac diabetic PCD company in Chandigarh, has a line of pharmaceutical products that off both Orthopaedic Nasal Drops Anti Diabetic Gynecology/ Pediatrics Gastroenterology Cardiac & Dermatology. This company has over 1000 FSSAI and DCGI-certified products in its portfolio has a strong PAN India distribution network and it works with over 250 pharma clients. With quality service delivery, especially observing timely delivery and embracing modern technology, Life Vision Healthcare upholds strict quality standards and has a vast distribution network. 

Sanify Healthcare

Sanify Healthcare is one of the leading Cardiac Diabetic PCD companies in India which deals in more than 300 products of pharma franchise at reasonable prices. The company also operates manufacturing facilities of WHO, GMP, and ISO certified for producing the highest quality products with beautiful packaging. To deliver the ranges of diabetic, ENT, gynaecology, cardiac, pediatric, and antibiotics, Sanify Healthcare offers monopoly rights and promotional tools all certified by DCGI and FSSAI. The production is also operated with modern technology for the products to be delivered on time with a guarantee of delivery across the country.

Neuracle Lifesciences 

Neuracle Life Sciences is one of the prominent pharmaceutical firms having its subdivisions as Biopolis, Micropolis, and Infertility. The company has a large portfolio of DCGI and FSSAI-approved products such as antidepressants, antiepileptics, antipsychotics, anti-addiction, antispasmodic, anxiolytics and more. They have over 300 products through license manufacturing and are also involved in neuropsychiatry. They have a well-trained skilled R&D department that deals with new formulations and have a warehouse for the storage of drugs. 

[petnews2day]

Greyhound Racing | Campaigns | RSPCA

New Post has been published on https://petnews2day.com/pet-industry-news/pet-charities/greyhound-racing-campaigns-rspca/

Greyhound Racing | Campaigns | RSPCA

We’ll cut to the chase, greyhound racing has no place in modern society.

Dangerous? You bet.

Many are familiar with the sport where greyhounds race around a track, chasing a mechanical hare to the finish line. 

Once a sport deeply ingrained in British culture, greyhound racing’s popularity is thankfully declining. This is a positive reflection of a modern and conscientious society, one where the risk of suffering in the name of fun isn’t tolerated. Sadly, it’s still legal and enjoyed at the bookmakers and by spectators.

Wales is one of ten countries where commercial greyhound racing still takes place – alongside England, Scotland and Ireland.

It’s time to face the facts

Greyhound racing endangers dogs to painful injuries and death.

Data from Hope Rescue demonstrates that Wales is, too often, the final stop for unwanted, injured and poorly performing racing greyhounds from Ireland and England.

Between 2018 and 2021, Hope Rescue’s Amazing Greys project helped over 200 racing greyhounds.

Of these dogs, 40 endured serious, career-ending injuries. These included severe fractures needing significant vet care, amputation or orthopaedic repair.

The true number of injuries in Wales is difficult to know, due to there being no vet at the track and no requirement to publish the number of injuries or deaths.

Wales has no greyhound-specific regulations and its last remaining track is not licensed. However, licensing doesn’t solve the issue and doesn’t protect dogs.

 Data from GBGB show that over 2,000 greyhounds died and nearly 18,000 injuries were recorded from greyhound racing between 2018 and 2021.

By the age of 3.5 years old, 50% of greyhounds are no longer racing.

By five years old, 90% of greyhounds are no longer racing.

Around 6000 greyhounds leave the licensed industry each year, with many needing to find new homes. This leaves charities and rescue organisations to pick up the pieces.

Many dogs aren’t properly socialised, trained or provided healthcare.

Sadly, the industry is poorly and inconsistently regulated. There’s little formal education for non-vet people working within the independent racing sector.

At its peak, there were 250 licensed tracks in the UK. Today, only 20 remain with a further two that are unlicensed in Great Britain.

Getting to the finish line

Animals’ lives are not to be gambled. Yet every year, thousands of dogs face a life of uncertainty, injury and even death in the name of sport, fun and profit.

The UK needs to get up to speed. We think this is possible to do through a phase-out programme. This is a move that would protect future generations of greyhounds from the dangerous consequences of these races.

We’ve joined forces with our friends at Dogs Trust, Blue Cross, Hope Rescue and Greyhound Rescue Wales to make sure this happens.

In Wales, this seems entirely possible with its one remaining track, the Valley Greyhound Stadium. We’re encouraging the Welsh Government to commit to a phase-out of greyhound racing. We’re also hopeful England will follow suit.

With your help, there could be a better future for greyhounds. Join the movement today – Ready, set, take action.

*Not all of these dogs will have raced in Wales. Some may have finished their racing lives outside of Wales but were surrendered to the project due to their racing owners having links with the Welsh track.

[tasmiq]

Womanhood

You naturally emanate more than most

As a Muslim foremost

As a sole-daughter who's a doctor and wife, mother, daughter-in-law and sister

First as a brainy and soulful believing Muslim

With easy ability and little required effort

Deep, versatile and resilient

Second as a sole daughter, wife, mother, daughter-in-law and sister - all your family roles

Reflecting the sheer resilience you were blessed with

In your commendable ability to manage such vastness

Third as an unappologetic advocate of breast feeding motherhood

Of quaint physicality that miraculously birthed four sons

Unsurprisingly reared to assume formidable personalities

Fourth as a Doctor of healing

An Orthopaedic Surgeon at that

Excelling in a male dominated sector in the needed public sector

Finally fifth as the pioneer of us to turn 39

Just one more year to realise the Islamic significance of turning 40

A shining green heart that will be our foremost gratitude for the day!

[teleradiologyreporting]

How To Choose The Right Indian Teleradiology Partner

Teleradiology is a 21st century medium of interpreting radiological images ( CT scan, MRI, XRAY, Ultrasounds) with the potential to get the best results irrespective of time or place. 

India is recognized to have provided many trained personnel in the IT field, customer care, health & telemedicine across the globe. 

Before April 2020 teleradiology in India was confined to a handful of service providers. However, on March 25th, 2020 Ministry of the health of India officially made teleconsultations legal. On top of that, the outbreak of the COVID-19 pandemic led to a surge in Indian teleradiology providers in order to answer the need for huge volumes of HRCT chests done at every level from tier 3 to tier 1 city.    

During the pandemic, teleradiology was embraced by many radiologists in India as it could compensate for reduced ultrasound cases without risk of getting infected. As a result, many teleradiology service providers have emerged in India and are functioning presently.

As a client or hospital, settle what you want first putting your patient at the center. Whether you want to answer specific issues (such as night emergencies, delayed TAT, etc) or to enhance the quality of radiology services ( to improve the quality of reads and TAT).

With our experience of 12 years in this sector, we have put together handy tips that will guide you through choosing the best teleradiology service provider in India.

Quality of Teleradiology Service Provider

It’s tough to assess the impact of any diagnostic health Care Service by any sort of ratio or statistics. Referring Clinician satisfaction and client retention can be good indicators in general for assessing the quality of a given teleradiology Service Provider. Before signing a service level agreement the client should ask for access to prior reports by each of the Radiologists from the given Teleradiology Services provider or sample reports and check the profoundness by reporting style. Going one step further one may ask for a trial by assigning some random cases to the provider as per your needs. For example, an Orthopaedic Hospital can assign a few trial prediagnosed MRI joints or CT scan trauma studies with subtle tiny fractures. Or a General Hospital client can assign proven cases such as pulmonary embolism, acute appendicitis, thin subdural from the Emergency Room to test the efficiency.  

Hence it is necessary to integrate into the partnership deal with the teleradiology provider, a Continuous Quality Improvement (CQI).

Analyzing the peer review system in the workflow as to how it works, how quickly the images are routed for peer review can be important.

Assessment of experience of all reporting Radiologists in the field of required modalities and subspecialties is an important factor. Indian Radiology Practise is highly modality driven. The majority of radiologists in India practice ultrasound but do part-time teleradiology in a particular time slot or on weekends. You may have a Radiologist with 10 years of experience on his CV but is only occasionally reporting gastrointestinal CT scans or MRI joints. 

Large versus Small Panel Teleradiology Service Providers

The size of the teleradiologist’s panel is an important criterion for searching for the right match for your organization. The optimum size of the panel to cover all 24 hours is important at the same time stability of the teleradiologists with constant names is key to develop trust for a long term relationship with the referring clinician. Hiring a large panel of teleradiologists for a small hospital will doesn’t make sense always. Generally, large panel radiologists have a high turnover rate. Continuously changing the names of the radiologists will hamper the trust-building between the referring surgeon and the teleradiologists.  

Besides panel size turnover rate of radiologists may indicate the stability of the group. Large panel teleradiology providers in India generally comprise multiple part-time radiologists who otherwise are doing ultrasound practice at their clinics. Such groups may lack a teleradiology culture. Imagine a CT abdomen scan for a suspected case of bowel perforation being read by a sonologist within his time slot provided by the telerad provider who is looking for gas under the diaphragm on the scanogram. 

In contrary to an experienced teleradiologist who is reporting hundreds of CT scans a day sitting for hours in his office who is trained to look for even a tiny extraluminal air. 

In contrast to the large groups small but stable panels of teleradiology service providers who are full-time teleradiologists are at an advantage of building trust and a comfort level with the referring clinicians due to low turnover rates. 

We need to understand the difference between the optimum sized panels of stable, full-time teleradiologists versus large panels of revolving part-time radiologists.

Most of the large groups employ radiologists who are full-time ultrasonologists and reports cross-section studies (CT or MRI scans) on a part-time basis or on weekends, so the size of the teleradiology panel is a factor in bethinking. However, the large panels have many panel radiologists needed to provide coverage which is an advantage.  

Communication Of Critical Findings And Coverage

In emergency cases, the consequences for the patient can be severe if there is no direct communication between the referring surgeon or critical care physician and the reading radiologist.

 Ideally, a teleradiology service provider should have a protocol outlined for the proactive steps required to communicate the emergency findings or unexpected findings. For example, the policy may be only to contact the referring clinician on phone in the case of a life-threatening disease or other situations such as clinically unsuspected cases such as metastasis. Also, it is equally important that the reporting radiologist himself receives the call immediately to clarify the clinician’s doubt in an emergency situation. The use of mobile SMS or WhatsApp can add value. 

Needless to mention, a good teleradiology service provider should be covering 24/7 for 365 days.

Work Flow and Turnaround Time

Turnaround time is the time frame between when the request of a teleradiology service provider is ordered and when the report is sent back. A good turnaround time for acute stroke should be between 10 to 30 minutes. Teleradiology service providers must have a case prioritization feature inside the PACS software. However, it is also important to give the reporting teleradiologist a comfortable environment by allowing longer Turn around time for nonemergent subspeciality focus cases.

Technology and Infrastructure

As far as IT infrastructure is concerned there are three types of teleradiology service providers in India

1. self-developed commercial IT and reading services. 2. teleradiology reading service providers that have developed their own IT ( although IT is not available commercially). 3. teleradiology reading service providers using third-party IT solutions.

HIPAA compliance

Health Insurance Portability and Accountability (HIPAA) rule that guard patient information about their health. For a standard teleradiology service provider, it is necessary to comply with HIPAA rules, which are concerned about the privacy and security of patient information.  

Teleradiology services in India are in general 20 to 40% cheaper compared to US telerad providers.   

At the end, before hiring a teleradiology partner one should be clear about the goals your organization wants to achieve. An Indian teleradiology partner can be equally effective as a USA teleradiology provider if chosen appropriately.

[clinicalsurgery]

Orthopaedic Clinic Versus a Pandemic – Snapshot of Patient Behaviour, Safety Measures and their Impact on Clinic Workload at Six Months after Onset of Covid-19 in Open Access Journal of Medical and Clinical Surgery by Dalun LEONG

Abstract

Background: The initial impact of Covid-19 pandemic has led to drastically reduced outpatient attendances. This resulted in a backlog that potentially overwhelms the existing outpatient clinic capacity. The challenge in addressing this backlog includes a ‘new normal’ outpatient clinic set-up that mandates safe distancing measures. Our study reviewed the patient behaviour and the clinic workload changes in the first six months after the pandemic onset.

Methods: Clinic workload data from January 2020 to June 2020 were compared to that from the same time of the 4 preceding years (2016-2019). These outpatient data were categorised into cancellations, actualised appointments and no-shows. The projected backlog was determined from these data. The necessary resources required to cope with this backlog were projected over the subsequent 6 or 12 months.

Results: Our results suggested that the overall decrease in the actualised appointments in the first 6 months of 2020 was mainly due to cancellations and its highest rate was in May at the height of Singapore’s Covid-19 pandemic. The cancellation rate initiated by patient remained unchanged compared to previous years. The 20% no-show rate was also similar when compared to previous years.

Conclusion: This suggested that patient behaviour in clinic attendance persisted even in the setting of a pandemic. To flatten the backlog curve within 6 months, our outpatient clinic must operate at 160% capacity. The urgency to address the increased workload must be balanced cautiously against the needed safe distancing. Options such as telemedicine are among some of the adjuncts explored to circumvent the challenge.

Keywords: Covid-19, Ambulatory, Backlog, Clinic, Telemedicine

Background

The coronavirus 2019 (Covid-19) pandemic has drastically transformed healthcare services globally. Since the confirmation of the first Covid-19 positive patient [1] on 23rd January 2020, Singapore has progressively ramped up safety measures such as safe distancing to mitigate the rapid spread of the virus. Dorscon Orange Alert [2,3] was implemented on 7th February 2020 in response to the global surge Covid-19 cases. The Singapore government subsequently implemented a ‘circuit breaker’ [4] on the 7th April 2020 with enforced movement restrictions in the community. This measure was relaxed on 2nd June 2020 with safe distancing measures[5]. The pandemic impacted various aspects of the country including the healthcare sector.

Changi General Hospital serves an approximate 1.6 million population on the east side of the island. The orthopaedic clinic is the busiest clinic in this tertiary hospital, and it has an annual actualised attendance of approximately 68000 in 2019. There was a significant decrease in the actualised attendances due to safety concerns and measures [5]. This resulted in a backlog [6] that potentially overwhelms the existing outpatient clinic capacity. The challenge in addressing this backlog includes a ‘new normal’ environment that mandates safe distancing measures. The current study reviewed the patient behaviour and the clinic workload changes in the first six months after the pandemic onset.

Methods

The statistics of the orthopaedic clinic obtained from the Health Systems Intelligence unit was after Institutional Review Board (IRB) approval. The clinic data from January 2016 to June 2020 were obtained. The number of bookings per month were determined. These bookings were then divided into cancelled, actualised and no-shows. An actualised appointment is a booking where the patient attended the appointment. A no-show is a booking where the patient did not attend the appointment. A cancellation is a booking where the clinic or the patient changed it to usually a later date. A comparison of the number of actualised visits, no-show and cancellation for January to June 2020 was made. A comparison of the same period in each year from 2016 to 2019 was made. The period of January to June 2020 was selected to observe the trend in clinic attendance before, during and after the circuit breaker (07 April to 01 June 2020). The decrease during this six-month period was determined and compared with the same period in 2016 to 2019. The referral trend and numbers were determined and correlated to the circuit breaker.

The backlog was determined from the cancellations and rejections of a new appointment. The clinic resources from July 2020 onward was determined from historical data and the backlog was projected onto it. The backlog was categorised into new cases and follow-ups. The number of follow-ups generated from a new case was by using new case: follow-up ratio in financial year 2019 workload statistics over 6 months. The number of follow-ups generated from an existing follow-up was by the total number of financial year 2019 follow-up appointments divided by the number of unique patients. The historical workload for radiological and rehabilitation services support for each clinic session is obtained. The ratio of physician consultation to rehabilitation and radiology appointments were analysed. The data was analysed by R and the figures were visualised with Tableau.

Results

There is a significant change in the actualised attendance, with an average decrease of 30% from January to June compared to previous years 2016 to 2019 (Figure 1). The most significant decrease of 50% compared to previous years was in April to June 2020 and coincided with the ‘circuit breaker’ (07 April to 01 June 2020) (Figure 2). There was more follow-up affected than the new cases. The no-show rate remained constant at 20% similar to previous years. The number of cancellations inversely relates to the number of actualised appointments.  The cancellations were by either patient or the clinic. The number of patient cancellation remained the same compared to previous years. The clinic cancellations followed a clinical records review to identify chronic stable patients who did not require any urgent or emergent care in accordance to prevailing ministry guidance. The backlog (Figure 3) was determined by the number of cancellations of new cases and follow-ups. A new case on a historical average resulted in 3 more follow-up visits in one year and a follow-up visit resulted in 2 more visits in one year. This is approximately 25,000 cases. When this number is converted into clinic sessions (3.5 hour per session), an additional 967 sessions are required. This equates to about 40 additional sessions per week if the backlog is cleared in 6 months. The referrals decreased in number for a limited period (Figure 4) and reflected a possible change in the behaviour of the patient and doctor that governs a referral. This resulted in a decrease in ‘lead time’ during the circuit breaker. The ‘lead time’ is a criterion to monitor referrals that exceeds a waiting time of more than 60 days. For every 10 consultations, there are 6 x-rays orders, 6 physiotherapy referrals and 1 occupational therapy referral (Figure 5).

Discussion

The overall decrease in the actualised appointments in the first 6 months of 2020 was mainly due to cancellations and was at its highest rate of 50% in May (middle of circuit breaker). The cancellation rate by patient remained unchanged compared to previous years. The 20% no-show rate was similar to previous years [7,8]. Studies [9,10] showed no-show correlates with the patient profile such as age group, waiting time to appointment and socio-economic status. The current study suggests such patient behaviour persists in a pandemic. We postulate that the transient period of referral decrease (Figure 4) was due to a variety of reasons such as patient health seeking behaviour, threshold to refer, decreased attendances at the emergency department, polyclinics and general practices. The triaging of essential and non-essential follow up is to create capacity for the hospital to cope for a COVID 19 surge in the community. It also facilitated the implementation of safe distancing measures in the clinic during the circuit breaker period.

Conversely, the resumption of clinic services after the circuit breaker was constrained by safe distancing measure. The clinic utilized all available consultation rooms, expanded its physical space by sitting attendees outside its boundary, staggered the appointments and optimized the clinic staffing. Staff optimization included ‘rationing’ of annual leave with planned call back due to service exigency and recalling staff deployed at other frontline facilities. The downstream care providers such as radiology and rehabilitation services were enhanced to prevent a chokepoint. To flatten the backlog curve, the clinic aimed to function at 160% clinic workload over a 6-month period to maintain timely patient care. This needs an additional 40 clinic sessions per week with extension of consultation hours each day or weekend clinic concomitantly with locum physicians and support staff. These measures were initiated and the clinic adhering closely to ministry guidelines, had resumed 80% of its pre-pandemic workload at the time of writing. Despite readied resources, the urgency to address the increased workload was balanced cautiously against the needed safe distancing and innovative new model of care such as telemedicine are being reviewed for implementation.

Telemedicine [11-13] is an option for discussing investigation reports, follow-up attendances of stable conditions and rehabilitative purposes. Other advantages include reduction of no-show rate, monitor homebound patients and helps a patient who has difficulty taking time off work. Amongst the challenges to its expedient application and effectiveness are technology savviness, adaptation, cost of setting up and medico-legal clearance. The nature of orthopaedic consultation requires imaging studies but telemedicine is applicable for selected conditions. There are limitations in the current study. The clinic sessions are assumed to be identical. However, a session can be entirely for follow-up or new case or a mixture. The number of appointments per session is dependent on this and the subspecialty. The strategy is on the assumption of full clinic staffing and support services.

Conclusion

During a pandemic, there was no significant change in patient cancellation, no-show, and a transient period of referral decline during the circuit breaker was observed. The main factor that effectively achieved the safe distancing instructed by the ministry was postponement of stable cases with return advice. Despite stretching the clinic resources to match an above normal workload to achieve timely patient care, the effectiveness is constrained by the same safe distancing measures, and new ways of patient care such as telemedicine is deployed. These factors that affect clinic workload warrants a future review to establish a clinic workflow for a pandemic.

Regarding our Journal: https://oajclinicalsurgery.com/ Know more about this article https://oajclinicalsurgery.com/oajcs.ms.id.10028/ https://oajclinicalsurgery.com/pdf/OAJCS.MS.ID.10028.pdf

[maximizenetwork]

Global Natural Biomaterials Market-Industry Analysis and Forecast (2020-2027)- By Product, Application, and Region.

The global natural biomaterials market was recorded at US$ 62.48 Bn in terms of value in 2019 and is expected to reach 184.50 Bn by 2027, at a CAGR of 15.5% during a forecast period. Major attention on ongoing research and development activity estimated to cover 40% of Natural Biomaterials market growth.

Market Definition:

Natural biomaterials are any material reserved from plants and animals which is utilized to extend, interchange, or repair body organ and tissues. Biomaterials are separated into two types viz. synthetic and natural biomaterials. The natural biomaterials are taken from plants or animals.

The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and disrupters in the report, and the same is reflected in our analysis.

Market Drivers and Restraints:

Various enduring development in the gene therapy and medicine industries are considered as one of the major driving factors for the natural biomaterials market in terms of volume and value during the forecasted period. Convenience of raw materials and various application from end user sector is expected to boost the market. Advancement in technology and manufacturing process with developed equipment in developed and developing countries are boosting the market growth. Accumulative aged residents hence are disposed to several chronic diseases is another factor rushing demand in the global natural biomaterials market. Additionally, budding application of biomaterial in numerous advanced medical technologies like plastic surgery, tissue engineering, drug delivery devices, and other medical implants are going to open numerous opportunities for the market growth. On the other hand, use of the targeted material for tissue designing and rising cases of knee and hip replacement surgeries application is further measured as a foremost growth factor.

However, the high making cost of natural biomaterials and strict government regulations allied with the use of biomaterials materials are expected to hamper growth of the market during the forecast period.

Natural Biomaterials Market Segment analysis:

By application of natural biomaterials, plastic surgery sector was the highest propelling segment, accounting for over 43% of the market share in 2019. Development and advancement in the cosmetic industry with bending interest of the youth to look beautiful is considered as a major growing factor for the targeted segment in the coming year. Growing population in the Asia Pacific region is projected to boost the targeted market in the near future. Natural Biomaterials based products are expansively chosen as a material to treat or repair the damaged face and body part owing to the rising cases of accident in the region.

Natural Biomaterials Market Regional Analysis:

Regionally, the Asia Pacific is expected to dominate the natural biomaterials market and is expected to grow at a CAGR of X.35 % during the forecast period owing to the existence of impressive key players in the market. Developing regions like India, China, and Japan are considered as the major contributors for the natural biomaterials market growth in the Asia Pacific region. In 2019, in China market size was valued XX Bn and is expected to increase by US$ XX Bn in the coming years. Ongoing research and development activity is recorded as one of the key factor to drive the regional market demand.

After APAC, North America stood up on second position in terms of product acceptance owing to the product positive impression amongst the growing population. On the other hand, developed healthcare infrastructure, high healthcare spending, rising cases of cardiovascular diseases across the region is boosting the product demand.

The objective of the report is to present a comprehensive analysis of the Global Natural Biomaterials Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Natural Biomaterials Market dynamics, structure by analysing the market segments and project the Global Natural Biomaterials Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Natural Biomaterials Market make the report investor’s guide. Scope of Natural Biomaterials Market

Global Natural Biomaterials market, By Product

• Hyaluronic Acid • Collagen • Gelatin • Heparin • Fibrin • Cellulose • Chitosan • Others Global Natural Biomaterials market, By Application

• Regenerative Medicine • Cardiovascular • Orthopaedic • Dental • Plastic Surgery • Immunotherapy • Stem-Cell Therapy • Tissue Engineering • Gene Therapy • Other Global Natural Biomaterials Market, By Region

• Asia Pacific • North America • Europe • Latin America • Middle East & Africa Key Players Operating the Natural Biomaterials Market,

• Mimetis Biomaterials • Botiss Biomaterials • BASF • Biomet • Invibio • Royal DSM • Corbion • Medtronic

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in  Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.</p>

Contact info: Name: Vikas Godage Organization: MAXIMIZE MARKET RESEARCH PVT. LTD. Email: sales@maximizemarketresearch.com Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com

[orthopedicdevicesmarket-blog]

Orthopaedic Devices Market

Orthopaedic Devices Market is estimated to surpass $ 31.88 Billion marks in 2019 and reach USD 41.56 Billion by 2024, at a Compound Annual Growth Rate (CAGR) of 4.4% during the forecast period 2016-2024 globally.

High prevalence of orthopedic conditions such as degenerative bone disease and rising geriatric population are some of the major market drivers. The increasing number of road accidents are expected to further propel market growth. Additionally, obesity and sedentary lifestyles resulting in early onset of musculoskeletal conditions are expected to boost market expansion during the forecast period.

Orthopaedic Devices MarketOrthopaedic Devices Market1 Rising awareness regarding the availability of innovative products among patients is pushing hospitals to constantly upgrade devices and services they offer. In addition, reimbursement coverage of orthopaedic treatments has fuelled adoption of advanced surgeries. These factors encourage customers to opt for advanced and high-priced devices, thus adding to the total revenue generation of the sector. Along with the introduction of advanced products, prices for their older versions reduce significantly. This helps in driving the adoption of advanced devices in developing countries where medical reimbursement is partially available or is completely unavailable. Such regions include Asia Pacific, Latin America, and the Middle East and Africa. The cumulative effect of these activities is expected to result in increasing procedural volume and thus, fuelling the growth of the Orthopaedic Devices Market.

The growing geriatric population base is highly susceptible to developing bone-related diseases such as osteoporosis and osteoarthritis. As per WHO, the global population over 60 years is expected to reach 2 billion by 2050. The increasing base of the elderly population will create significant demand for various orthopedic implants and devices. An increasing prevalence of diabetes and obesity, lack of physical activity, poor diet intake and a rising trend of smoking and alcohol consumption will fuel orthopedic devices market demand over the forecast years. New innovations in the field of osteology should boost the development of cost-effective devices. Technological advances in 3D printing, robot-assisted surgical procedures, and smart implants will represent high impact driving factors for the global industry revenue.Orthopaedic Devices Market2 Joint reconstruction held over 40% of the orthopaedic devices market share with expectations to witness more than 3% CAGR. Increasing geriatric population, the rising prevalence of osteoporosis and osteoarthritis and soaring incidence of road accidents and sports injuries will drive demand for artificial joint reconstruction devices.

North America Orthopaedic Devices Market accounted for the highest revenue in 2017 and is projected to grow at a significant rate during the forecast period. U.S Orthopaedic Devices Market share held over 90% of regional revenue. Increasing adoption of advanced orthopaedic solutions and improved healthcare infrastructure will stimulate business growth. Rising R&D support to develop innovative products should also augment industry expansion.

Maximize Market Research has comprehensively analyzed Orthopaedic Devices Market emphasizing on each segment keeping global and regional dynamics in perspective. The driving forces, as well as considerable restraints, have been explained in depth to attain a balanced scenario. The report classifies Orthopaedic Devices Market into various segments such as Products, Applications, and Regions providing a thorough understanding of the Orthopaedic Devices Ecosystem. Importantly, the report delivers forecasts of the market, giving an insight into the future opportunities that exist in the Orthopaedic Devices Market.

The Scope of the Orthopaedic Devices Market Report:

  Orthopaedic Devices Market By Product:

Joint Reconstruction, Spinal Devices, Trauma Fixation Devices, Orth biologics, Arthroscopic Devices

Orthopaedic Devices MarketBy Application:

Hip, Knee, Spine, Craniomaxillofacial, Dental, Sports Injuries, Extremities, and Trauma (SET)

Orthopaedic Devices MarketBy Geography:

North America, Europe, Asia Pacific, Middle East & Africa and Latin America

Orthopaedic Devices Market-Key Players:

Medtronic PLC

Stryker Corporation

Zimmer-Biomet Holdings, Inc.

DePuy Synthes

Smith and Nephew PLC

Aesculap Implant Systems, LLC

Conmed Corporation

Donjoy, Inc.

NuVasive, Inc.

Biomet, Inc.

Wright Medical Group, Inc.

Globus Medical, Inc.

Johnson & Johnson

Arthrex Inc.

RTI Surgical Inc.

AlloSource

DePuy Synthes

DJO Global

4WEB Medical

Acumed

Advanced orthopaedics

Aesculap Implant Systems

Alphatec Spine

AMEDICA

Anika Therapeutics

Success Stories: Key Industry Players:

Globus Medical, Inc.

Johnson & Johnson

Arthrex Inc.

RTI Surgical Inc.

  For more information visit:

https://www.maximizemarketresearch.com/market-report/orthopaedic-devices-market/11284/

This Report Published By

Maximize  Market Research Company

[hauntedarcadestudentblr]

Medical Exoskeleton Market 29.4% CAGR Seeking Excellent Consumption Growth

An off-the-shelf report on Medical Exoskeleton Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as type/components/ application/industry verticals/ end-users are analyzed with robust research methodology which includes three step process starting with extensive secondary research to gather data from company profiles, global/regional associations, trade journals, technical white papers, paid databases etc. followed by primary research (interviews) with industry experts/KOLs to gain their insights and views on current scenarios and future scope of the market as well as validating the secondary information, further internal statistical model is used to estimate the market size and forecasts till 2027.

The global medical exoskeleton market accounted to US$ 96.7 Mn in 2018 and is expected to grow at a CAGR of 29.4% during the forecast period 2019 – 2027, to account to US$ 1,023.0 Mn by 2027.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPTE100000663/

The key players influencing the market are:

 Market Insights

Increase In The Number of Orthopaedic Surgeries

 The rise in orthopedic surgeries is majorly driven by the operations done for the replacements of the knee and hip joints. The surgeries have been done for the amputations of limbs due to the increasing rate of damages or injuries caused by road accidents or various diseases. The rising number of operations for amputation are observed for patients who have diabetes and also have developed a condition of gangrene. For instance, according to the U.S. Agency for Healthcare Research and Quality, in the United States, approximately replacement surgeries are performed per year. For the deteriorating joints, the knee replacement surgeries have performed in the geriatric population. Knee replacement is among the most commonly performed orthopedic procedures. The number of surgeries is increasing due to the rising chronic conditions, including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and osteoporosis. For instance, according to a report published in 2018 of Healthline Media, rheumatoid arthritis (RA) affects 41 in every 100,000 people per year, and near round, 1.3 million Americans have RA.

 This report contains:

 ·         Market sizing for the global Medical Exoskeleton Market.

·         Compare major Medical Exoskeleton Market providers strategies and approaches to the challenges they face

·         Analysis of the effects deglobalisation trends may have for Medical Exoskeleton Market providers

·         Profiles of major Medical Exoskeleton Market providers

·         7-year CAGR forecasts for Medical Exoskeleton Market -intensive vertical sectors

 Medical Exoskeleton Market- Global Analysis to 2027 is an expert compiled study which provides a holistic view of the market covering current trends and future scope with respect to product/service, the report also covers competitive analysis to understand the presence of key vendors in the companies by analyzing their product/services, key financial facts, details SWOT analysis and key development in last three years. Further chapter such as industry landscape and competitive landscape provides the reader with recent company level insights covering mergers and acquisitions, joint ventures, collaborations, new product developments/strategies taking place across the ecosystem. The chapters also evaluate the key vendors by mapping all the relevant products and services to exhibit the ranking/ position of top 5 key vendors.

Medical Exoskeleton Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2018 – 2027, considering 2018 as the base year and 2018 – 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Key Benefits

Ø  This report provides a detailed study of Medical Exoskeleton Market \ trends and forecast from 2020 to 2027, which assist to identify the prevailing market opportunities.

Ø  In-depth coverage of the global Medical Exoskeleton \ market that includes drivers, restraints, and opportunities, helps professionals to understand the market behavior in a better way.

Ø  This study further includes market analysis in terms of type and applications.

Ø  Detailed study of the strategies of key leaders, partnerships, and acquisitions in the   Medical Exoskeleton Market is provided.

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPTE100000663/

About Us:                   The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us: Call: +1-646-491-9876 Email: sales@theinsightpartners.com

[rohinic123-blog]

Immunoprecipitation Market  is Expected to Expand at an Impressive Rate by 2027

Global Immunoprecipitation Market: Overview

Immunoprecipitation is a process of separating protein from biological samples. Here, the protein is isolated using a specific antigen. The global immunoprecipitation market is expected to grow at a healthy rate during the forecast period. The growing trend of clinical researches is expected to augment the global immunoprecipitation market.

An upcoming Transparency Market Research (TMR) report sheds some light on size, share, trend and growth factors affecting the global immunoprecipitation market.

Report Overview @

https://www.transparencymarketresearch.com/immunoprecipitation-market.html

Global Immunoprecipitation Market: Notable Developments

Some of the notable developments in immunoprecipitation area are: -

Chromatin immunoprecipitation (ChIP) is an old method; however, in 2018 new technique was developed in chromatin immunoprecipitation that identifies DNA sequences associated in vivo proteins. The combination of DNA fragments and binding protein can be studied by sequencing and microarrays along with an antibody that can distinguish a protein.

In April 2019, GenScript Biotech Corporation has entered into a strategic collaboration with REMD Biotherapeutics Inc, to develop renewed immunotherapy drugs using bispecific antibodies.

Apart from these key developments, the global immunoprecipitation market is competitive. Some of the leading players in the global immunoprecipitation market are Merck KGaA (Germany), Abcam (UK), Thermo Fisher Scientific (US), GenScript. (US), Cell Signaling Technology (US), Bio-Rad Laboratories (US), and Geno Technology (US). These leading players are adopting both inorganic and organic strategies to capture the competitive global market. They focus on collaborations, partnerships, mergers and acquisition.

Global Immunoprecipitation Market: Drivers & Restraints

Factors leading the global immunoprecipitation market towards expansion are as follows.

Disease Targeted Drugs to Augment Global Immunoprecipiation Market:

Rising number of cancer cases and need for precision medicines are likely to drive the global immunoprecipitation market. Increasing number of autoimmune diseases to create a demand for immunoprecipitation to probe into the disease mechanism and develop a disease oriented drug. Rising geriatric population and diseases associated with age are also expected to drive the market. Increasing cardiovascular diseases, orthopaedic diseases and need for precision medicines to treat them are also expected to expand the global immunoprecipitation market. Furthermore, rising importance of stem cell therapy to develop cell based treatment is another factor that is expected to drive the global immuunoprecipitation market.

Planning To Lay Down Future Strategy? Request Brochure Of Immunoprecipitation Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68366

Trending Genomics to Boost Growth in Global Immunoprecipitation Market

Advances in genomics such as genomic alteration by transforming cells have led to development of new studies and methods. This, in turn increases the demand for immunoprecipitation. Thus, the global immunoprecipitation to see a healthy expansion in the upcoming years.

Availability of alternate technologies for protein isolation is expected to hinder the growth of the immunopercipitation market during the forecast period.

Despite the restraints, the global immunoprecipitation market is likely to grow due to increasing occurrence of various types of cancer and many other chronic diseases.

To Obtain All-Inclusive Information On Forecast Analysis Of Immunoprecipitation Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=68366

Global Immunoprecipitation Market: Geographical Analysis

The global immunoprecipitation market is spread across five regions; they are North America, Latin America, Asia Pacific, Middle East & Africa, and Europe. Among these, Asia Pacific is projected to hold a major share in the global immunoprecipitation market. The factors that are expected to surge the market are rising awareness about precision medicines or disease targeted therapies, increase in research activities in biotechnology, rising governments support and investment in healthcare sector. Hence, the global immunoprecipitation market is expected to expand substantially during the forecast period.

More Trending Reports by Transparency Market Research –

Pharmerging Market –

https://www.prnewswire.com/news-releases/pharmerging-market-to-hit-us1-40-billion-by-2024–says-tmr-300800262.html

Request For Coronavirus Infection Market Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16940

[mmrseo]

Global Bio Ceramics Market

Global Bio Ceramics Market was valued US$ 2.73 Bn in 2018 and is projected to reach US$ XX at a CAGR of XX %.

Bio ceramics have transformed the field of medicine by giving hope of generating engineered human tissues. There have been great advances in bio ceramics, glasses and glass ceramics, and recently emphasis has shied towards the use of biomaterials especially for bone and dental tissue engineering.

By 2050, the world’s population aged 60 years and older is expected to total 2 billion, up from 125 million people aged 80 years or older will led to rising incidences of osteoarthritis thereby resulting into increase in bio ceramics consumption for knee and hip joint replacements and implants. Partial joint replacements and minimally invasive techniques cost are expected to open new opportunities for market growth over the forecast period. However, fluctuation in alumina prices and medical polymers which have properties similar to bio ceramics is expected to limit the industry expansion.

Alumina segment dominated the global bio ceramic market comprising 62% in 2017. Bio-inertness, hardness and high abrasion resistance property has resulted into extensive use of alumina implants for dental and joint applications. Growing demand for biocompatible materials to increase adoption by the patient’s body also to reduce the occurrence of infections post surgery is expected to augment demand for alumina during the forecast period.

Orthopaedic application segment accounted for major share in global bio-ceramic market, due to increasing surgical intervention trend for shoulder, knee, and hip implants. Consumption of bio ceramics for knee and hip joint replacements and implants is increasing due to growth in geriatric population.

Europe accounted for 40% of the global bio ceramic market, in 2017. Demand for dental applications in Germany, United Kingdom, Italy, and France. Changing population statistics in Europe have led to an increase in growing demand for healthcare facilities. Medical advancements has majorly contributed to the increasing use of the bio ceramics in a recent years. North America is the fastest growing region for bio ceramics and depicts enormous potential for growth in the future attributed to the increasing health care expenditure.

Amedica Corporation, Berkeley Advanced Biomaterials Inc., Bonesupport AB, CamBioceramics, Carborundum Universal Ltd, Ceramtec, Collagen Matrix, CoorsTek, Dentsply Sirona, Doceram Medical Ceramics GmbH, Jyoti Ceramic Industries Pvt. Ltd., Kyocera Corporation, Morgan Advanced Materials,Nobel Biocare Holding AG, Sagemax Bioceramics, Stryker, The Royal DSM Company and Tosoh Corporation are leading palyers involved in the global bio ceramic market. Scope of the Global Bio ceramics Market:

Global Bio ceramics Market, by Type:

• Bioinert • Bioactive • Bioresorbable Global Bio ceramics Market, by Material:

• Alumina • Zirconia • Calcium Phosphate • Calcium Sulphate • Carbon • Glass Global Bio ceramics Market, by Application:

• Dental • Orthopaedic • Others Global Bio ceramics Market, by Region:

• North America • Europe • Asia Pacific • Middle East & Africa • South America Key Player analyzed in the Report Global Bio ceramics Market:

• Amedica Corporation • Berkeley Advanced BioTypes Inc. • Bonesupport AB • CamBioceramics • Carborundum Universal Ltd. • Ceramtec • Collagen Matrix • CoorsTek • Dentsply Sirona • Doceram Medical Ceramics GmbH • Jyoti Ceramic Industries Pvt. Ltd. • Kyocera Corporation • Morgan Advanced Types • Nobel Biocare Holding AG • Sagemax Bioceramics • Stryker • The Royal DSM Company • Tosoh Corporation

This Report Is Submitted By @Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

 About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

 Contact Us:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH

Email: sales@maximizemarketresearch.com

Contact:  +91 9607365656

[traderspro]

Despite being near an all-time high, SYK might still offer an interesting value

Losing Trader Stops Doing This... Then Turned $10,000 Into $2.4 Million

This week, I’ve been turning my focus to Healthcare stocks, most particularly to the Healthcare Equipment industry of that sector. The most-established stocks in the industry all seem to be at or very near to all-time high levels – something that I believe is driven by broad fundamental strength among most of these companies as well as institutional interest in a sector and industry that may be better suited to succeed under current market and economic conditions than most others.

It takes a bit of a mindset shift for me to consider stocks that most analysts would correctly describe as strong growth stocks, with a long pattern of bullish momentum, as potential value plays. Focusing on value requires a bit of a contrarian preference, which makes these kinds of stock pretty counter-intuitive. Stocks trading at or near all-time lows, but that have solid fundamental strength tend to be an easier fit. That said, it is also true that even stocks in long, extended bullish trends can still offer interesting value opportunities if the conditions are right.

Stryker Corp (SYK) is one of the more interesting Healthcare Equipment companies I’ve evaluated so far this week. The stock’s bullish performance is very strong – it is up nearly 40% year to date, and only a few dollars below its all-time high, which was set at the beginning of this week. Whether or not the stock is overvalued, or actually has an interesting value proposition to consider, depends a bit on what metrics you prefer to focus. Let’s run the numbers, and I’ll let you decide.

Fundamental and Value Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties. SYK has a current market cap of $81.9 billion.

Earnings and Sales Growth: Over the last twelve months, earnings grew by 12.5%, while sales increased nearly 10%. In the last quarter, earnings improved by 5.32% while Revenues increased about 3.81%. These aren’t astonishing numbers, and it is also true that being able to consistently grow earnings faster than sales generally isn’t sustainable in the long term; but it is also difficult even for extremely well-run companies to do this on a consistent basis. That makes this pattern very interesting, and is a strong indication of strength. SYK’s Net Income versus Revenue is healthy, despite showing signs of erosion in its operating margins, as Net Income as a percentage of Revenues dropped from an impressive 24.9% in the last twelve months to 13.15% in the last quarter.

Free Cash Flow: SYK’s Free Cash Flow is modest, but healthy at $1.9 billion. That translates to a Free Cash Flow Yield of 2.33%. It is also growing nicely; at the beginning of 2018, SYK’s free cash flow was $1.1 billion, so this is an improving number that lends credence to the quality of the stock’s positive earnings growth pattern. Contrasted against the declining Net Income pattern, however, I would be interested to see if this number can continue to improve in the quarters ahead to provide even more confirmation of the company’s strengthening fundamentals.

Debt to Equity: SYK has a debt/equity ratio of .67, which is pretty conservative. SYK’s balance sheet shows $1.8 billion in cash and liquid assets versus about $7.9 billion in long-term debt. Their operating profile, despite its decline in the last quarter suggests that operating margins are more than adequate to service their debt, with good liquidity to draw on if needed as well.

Dividend: SYK pays an annual dividend of $2.08 per share, which translates to a yield of a little under 1%. More remarkable is the fact that their dividend payout is modest – at less than 50% of earnings per share, along with a consistent pattern of raising its dividend per share over the last eight years, with no cuts.

Price/Book Ratio: there are a lot of ways to measure how much a stock should be worth; but one of the simplest methods that I like uses the stock’s Book Value, which for SYK is $31.92 per share. At the stock’s current price, that translates to a Price/Book Ratio of 6.86, which seems high against a historical average of 4.9, which puts the stock’s “fair” value at about $156 per share. That’s about -28.5% away from the stock’s current price, which certainly marks the stock as overvalued; however the stock is also trading about 30% below its historical Price/Cash Flow ratio, which offers a long-term target price at nearly $285 per share. Which should you believe? I prefer to see the Price/Book and Price/Cash Flow ratio both below their respective averages to validate an undervalued status under the best circumstances; but I think SYK offers an interesting argument to consider the Price/Cash Flow ratio as the more useful metric in this case.

Current Price Action/Trends and Pivots: The red diagonal line traces the stock’s strong upward trend from December of 2018 to its all-time high around $223.50, reached just a few days ago. It also provides the base line for the Fibonacci retracement lines shown on the right side of the chart. The stock’s upward trend has really picked up steam since the beginning of June, with the stock current showing strong support in the $217 price area – just a couple of dollars below the stock’s current price – and immediate resistance at its recent peak at $223.50. How far might the stock go if it can break above that resistance? That’s a bit of a guess, no matter how you prefer to think about your analysis; but when you use the stock push above its last significant resistance gave it momentum to run from about $211 to $223.50, there is a case to make for a short-term bullish target at around $235. If, however, the stock drops below current support at $217, that previous resistance at $211 offers up the most likely next support level.

Near-term Keys: SYK’s fundamentals are among the strongest of the Healthcare Equipment stock’s I’ve considered so far this week. The question of value is in the eye of the beholder, but the stock’s next earnings report is due in the latter part of October. If the numbers I outlined earlier – Free Cash Flow and earnings and sales growth, for example – continue to show improvement, and the company’s pattern of Net Income improves, I would be even more inclined to consider SYK as a valid value opportunity than I am now. If you prefer to work short-term trading strategies, treat a break above $223.50 as a good sign to consider buying the stock or working with call options, with a bullish target within the next couple of months in the $235 range. If the stock breaks down below $217, it could offer an interesting opportunity to think about shorting the stock, or buying put options with an eye on support around $211 as the target price to close a bearish trade.

Todays Top Stock Picks - Sign Up Today - Limited Time - Click Here Now

[rdagade]

Global Bio Ceramics Market

Global Bio Ceramics Market was valued US$ 2.5 Bn in 2017 and is projected to reach US$ 5.121 at a CAGR of 9.38 %.

Bio ceramics have transformed the field of medicine by giving hope of generating engineered human tissues. There have been great advances in bio ceramics, glasses and glass ceramics, and recently emphasis has shied towards the use of biomaterials especially for bone and dental tissue engineering. By 2050, the world’s population aged 60 years and older is expected to total 2 billion, up from 125 million people aged 80 years or older will led to rising incidences of osteoarthritis thereby resulting into increase in bio ceramics consumption for knee and hip joint replacements and implants. 

Partial joint replacements and minimally invasive techniques cost are expected to open new opportunities for market growth over the forecast period. However, fluctuation in alumina prices and medical polymers which have properties similar to bio ceramics is expected to limit the industry expansion. Alumina segment dominated the global bio ceramic market comprising 62% in 2017. Bio-inertness, hardness and high abrasion resistance property has resulted into extensive use of alumina implants for dental and joint applications. Growing demand for biocompatible materials to increase adoption by the patient’s body also to reduce the occurrence of infections post surgery is expected to augment demand for alumina during the forecast period. 

 Orthopaedic application segment accounted for major share in global bio-ceramic market, due to increasing surgical intervention trend for shoulder, knee, and hip implants. Consumption of bio ceramics for knee and hip joint replacements and implants is increasing due to growth in geriatric population. Europe accounted for 40% of the global bio ceramic market, in 2017. Demand for dental applications in Germany, United Kingdom, Italy, and France. Changing population statistics in Europe have led to an increase in growing demand for healthcare facilities. Medical advancements has majorly contributed to the increasing use of the bio ceramics in a recent years. 

North America is the fastest growing region for bio ceramics and depicts enormous potential for growth in the future attributed to the increasing health care expenditure. Amedica Corporation, Berkeley Advanced Biomaterials Inc., Bonesupport AB, CamBioceramics, Carborundum Universal Ltd, Ceramtec, Collagen Matrix, CoorsTek, Dentsply Sirona, Doceram Medical Ceramics GmbH, Jyoti Ceramic Industries Pvt. Ltd., Kyocera Corporation, Morgan Advanced Materials,Nobel Biocare Holding AG, Sagemax Bioceramics, Stryker, The Royal DSM Company and Tosoh Corporation are leading palyers involved in the global bio ceramic market.

For More Information Visit@ https://www.maximizemarketresearch.com/market-report/global-bio-ceramics-market/22218/

Scope of the Global Bio ceramics Market:

Global Bio ceramics Market, by Type: • Bioinert • Bioactive • Bioresorbable Global Bio ceramics Market, by Material: • Alumina • Zirconia • Calcium Phosphate • Calcium Sulphate • Carbon • Glass Global Bio ceramics Market, by Application: • Dental • Orthopaedic • Others Global Bio ceramics Market, by Region: • North America • Europe • Asia Pacific • Middle East & Africa • South America Key Player analyzed in the Report Global Bio ceramics Market: • Amedica Corporation • Berkeley Advanced BioTypes Inc. • Bonesupport AB • CamBioceramics • Carborundum Universal Ltd. • Ceramtec • Collagen Matrix • CoorsTek • Dentsply Sirona • Doceram Medical Ceramics GmbH • Jyoti Ceramic Industries Pvt. Ltd. • Kyocera Corporation • Morgan Advanced Types • Nobel Biocare Holding AG • Sagemax Bioceramics • Stryker • The Royal DSM Company • Tosoh Corporation

This Report Is Submitted By @Global Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

 About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

 Contact Us:

Name: Saurabh Gandhi

Organization: MAXIMIZE MARKET RESEARCH

Email: sales@maximizemarketresearch.com

Contact:  +91 9607365656

[jamieclawhorn]

2 FTSE 250 dividend stocks yielding 5%+ that I’d buy with £2k today

To mark the start of the new ISA year, I’m looking for quality dividend stocks with growth potential. I’ve focused my attention on the FTSE 250. In my experience, this mid-cap index is often a good place to look for businesses that are profitable and successful, but still have room to grow.

A truly great business?

Two companies have caught my eye. The first of these is specialist plastics manufacturer Victrex (LSE: VCT). This firm’s PEEK and PAEK polymers-based parts are used in thousands of applications, including cars, aeroplanes and orthopaedic surgery.

Victrex has a strong track record of growth. Over the last five years, sales have risen by 29% to £326m. Pre-tax profits climbed 24% to £127.5m. The dividend has risen 32% over this period and shareholders have also received three generous special dividends.

As these figures suggest, this is a very profitable business, with an average operating profit margin of about 40% over the last five years. Such high margins suggest to me Victrex products are hard to substitute and have strong pricing power — good news for investors.

One final attraction is this business generates a lot of cash and has no debt. At the end of last year, net cash stood at £144.4m.

Is this the right time to buy?

Victrex shares have fallen 30% over the last six months, after management warned that weaker demand from car manufacturers and consumer electronics firms could slow growth this year.

The outlook is expected to improve during the second half of the year, although it’s too soon to be sure. Personally, I’m not too worried. I see this as a high quality business with good long-term prospects.

Although the shares still look pricey on 17 times 2019 forecast earnings, they offer a forecast yield of 5.2% that’s supported by the firm’s cash generation. In my view, now could be a good time to build a long-term holding in this company.

I’ve bought this 8% yield

My next pick is financial spread betting and CFD trading group IG Group Holdings (LSE: IGG). This sector has fallen out of favour with investors over the last year, due to the impact of new regulations limiting the amount of leverage that can be offered to non-professional clients.

This has had the effect of forcing traders to scale back their positions or provide more cash up front. As a result, IG’s revenue is expected to fall 12% to £503m during the current financial year.

IG shares have fallen 35% in 12 months and some investors have questioned whether the dividend is sustainable. However, like Victrex, IG is extremely profitable and has a cash-rich balance sheet.

The board says the payout will be left unchanged at 43.2p per share until earnings return to growth. That sounds reasonable to me, at least for a couple of years. In that time, I expect performance to improve as the group’s international growth and diversification continues.

IG shares currently trade on 11 times forecast earnings, with an 8% dividend yield. I’ve added some shares to my portfolio and rate this stock as a buy.

Investing For Income?

If you’re looking to supplement your salary or pension with regular dividends, then this special free investing report could be a great place to start! ‘A Top Income Share From The Motley Fool UK’ profiles a company that you’re bound to have heard of … but what you may have overlooked is the current near-6% yield on offer that our Motley Fool analyst believes is “comfortably covered by profits and by the firm’s cash flow”. Click here to claim your free copy now!

More reading

I think these 2 quality dividend and growth stocks could be perfect ISA additions

This FTSE 250 stock looks fully valued for now. Here’s where I’ve put my ISA cash instead

I would sell this 7.8% yielder and buy the FTSE 100 instead

Roland Head owns shares of IG Group Holdings. The Motley Fool UK has recommended Victrex. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

[fmihealthcare-blog]

Sports Medicine Market Volume Analysis, Segments, Value Share and Key Trends 2017-2022

Sports medicine, an upcoming healthcare field, involves the treatment of various injuries related to sports along with athlete evaluation with a view to improve the athletic performance. Sports sector has witnessed large participation of population in sports. The growth of the sports medicine market can be primarily attributed to the increasing sports injuries. Another aspect that is pushing the growth of the global sports medicine market is the growing technological advancements in the medicine and medical devices sectors that is introducing new products in the market. This has triggered the adoption of sports medicine by consumers on a large scale, thus widening its scope in various application areas. Moreover, influx of new modalities coupled with innovations in the field of regenerative medicine and allografts have contributed to the growth of the global market for sports medicine in recent years. Increasing number of players in the sports medicine, penetration of large players in this field, growing government support and increasing awareness are set to drive the growth of the sports medicine market. However, high prices are associated with sports medicine, especially orthopaedic implants which is challenging the growth of the global market.

The comprehensive research report on “Sports Medicine Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2022)”, skilfully crafted by Future Market Insights reveals various aspects of the global sports medicine market along with key product types and applications, the analysis of which can be used to achieve expansion milestones in the years to come. As per sports medicine market research study, projection is that the market is expected to expand at a robust CAGR of 7.4% throughout the 2017-2022 period of assessment.

4 Key Highlights on Global Sports Medicine Market

The global sports medicine market has been segmented by product type, by application and by region.

By application, the knee injury segment reflects high potential with respect to both market share and growth in the years to come. The prevalence of knee injuries is rising among the athlete population. This fact has called for quick and effective treatment of knee injuries, thus making it a more lucrative segment. The knee injury segment by application is anticipated to grow at the robust rate to reflect a market share of 32.3% as of 2017, thus leading the global market and this trend is anticipated to continue over the assessment period

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5173

The shoulder injury application segment is also gaining significant traction since last couple of years. This segment is projected to grow at a 7.4% CAGR during the period of forecast to reach a noteworthy market share by 2022 end. This segment stands second in terms of market value during 2017-2022 followed by ankle and foot injuries application category

North America is the largest and the most attractive region for the growth of the global sports medicine market pertaining to market share. The sports medicine market in North America region is projected to grow at CAGR more than 7.0% throughout the assessment period. With respect to market share, Europe stands second to North America growing at a high CAGR. Asia-Pacific excluding Japan (APEJ) region is also anticipated to show significant growth in the years to come

Body Reconstruction segment by product type is expected to lead the global market as it reflects a high market share of more than 40% as of 2017 growing at a robust CAGR throughout the period of forecast. Body support and recovery segment is the second largest segment during the assessment period

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-5173

Global sports Medicine Market: Competitive Scenario

The research report on global market for sports medicine has profiled several key players involved in sports medicine domain. Their detailed analysis with respect to product portfolio, company overview, recent developments and innovations, SWOT analysis and key financials has been included in this research report. Key players such as Arthrex, Inc., Smith & Nephew Plc., Stryker Corporation, CONMED Corporation, Zimmer Biomet Holdings, Inc., Mueller Sports Medicine, Inc., Wright Medical Group N.V., Medtronic Plc, Johnson & Johnson and Breg Inc., are profiled in this study.